New strategies in muscle-invasive bladder cancer: On the road to personalized medicine

Jay B. Shah, David McConkey, Colin P N Dinney

Research output: Contribution to journalReview article

Abstract

Bladder cancer remains one of the most deadly and expensive diseases affecting modern society. The options currently available to patients with muscle-invasive bladder cancer have remained essentially unchanged for the last generation. As the roles for surgery and chemotherapy in the management of this lethal disease have become better defined, so too have the limitations of these two treatment modalities. Despite the lack of groundbreaking clinical advances over the past two decades, recent years have witnessed a notable increase in the amount of promising preclinical and early translational research that will greatly improve our understanding of the molecular underpinnings of bladder cancer. If this momentum in bladder cancer research continues to build, it is likely that in the next 5 to 10 years we will be able to achieve our goal of bringing bladder cancer treatment into the age of personalized medicine.

Original languageEnglish (US)
Pages (from-to)2608-2612
Number of pages5
JournalClinical Cancer Research
Volume17
Issue number9
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Precision Medicine
Urinary Bladder Neoplasms
Muscles
Translational Medical Research
Disease Management
Drug Therapy
Therapeutics
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New strategies in muscle-invasive bladder cancer : On the road to personalized medicine. / Shah, Jay B.; McConkey, David; Dinney, Colin P N.

In: Clinical Cancer Research, Vol. 17, No. 9, 01.05.2011, p. 2608-2612.

Research output: Contribution to journalReview article

@article{27b84162220145c3b52a15323d66aa81,
title = "New strategies in muscle-invasive bladder cancer: On the road to personalized medicine",
abstract = "Bladder cancer remains one of the most deadly and expensive diseases affecting modern society. The options currently available to patients with muscle-invasive bladder cancer have remained essentially unchanged for the last generation. As the roles for surgery and chemotherapy in the management of this lethal disease have become better defined, so too have the limitations of these two treatment modalities. Despite the lack of groundbreaking clinical advances over the past two decades, recent years have witnessed a notable increase in the amount of promising preclinical and early translational research that will greatly improve our understanding of the molecular underpinnings of bladder cancer. If this momentum in bladder cancer research continues to build, it is likely that in the next 5 to 10 years we will be able to achieve our goal of bringing bladder cancer treatment into the age of personalized medicine.",
author = "Shah, {Jay B.} and David McConkey and Dinney, {Colin P N}",
year = "2011",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2770",
language = "English (US)",
volume = "17",
pages = "2608--2612",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - New strategies in muscle-invasive bladder cancer

T2 - On the road to personalized medicine

AU - Shah, Jay B.

AU - McConkey, David

AU - Dinney, Colin P N

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Bladder cancer remains one of the most deadly and expensive diseases affecting modern society. The options currently available to patients with muscle-invasive bladder cancer have remained essentially unchanged for the last generation. As the roles for surgery and chemotherapy in the management of this lethal disease have become better defined, so too have the limitations of these two treatment modalities. Despite the lack of groundbreaking clinical advances over the past two decades, recent years have witnessed a notable increase in the amount of promising preclinical and early translational research that will greatly improve our understanding of the molecular underpinnings of bladder cancer. If this momentum in bladder cancer research continues to build, it is likely that in the next 5 to 10 years we will be able to achieve our goal of bringing bladder cancer treatment into the age of personalized medicine.

AB - Bladder cancer remains one of the most deadly and expensive diseases affecting modern society. The options currently available to patients with muscle-invasive bladder cancer have remained essentially unchanged for the last generation. As the roles for surgery and chemotherapy in the management of this lethal disease have become better defined, so too have the limitations of these two treatment modalities. Despite the lack of groundbreaking clinical advances over the past two decades, recent years have witnessed a notable increase in the amount of promising preclinical and early translational research that will greatly improve our understanding of the molecular underpinnings of bladder cancer. If this momentum in bladder cancer research continues to build, it is likely that in the next 5 to 10 years we will be able to achieve our goal of bringing bladder cancer treatment into the age of personalized medicine.

UR - http://www.scopus.com/inward/record.url?scp=79955485574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955485574&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2770

DO - 10.1158/1078-0432.CCR-10-2770

M3 - Review article

C2 - 21415213

AN - SCOPUS:79955485574

VL - 17

SP - 2608

EP - 2612

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -